FDA Approves Atezolizumab for ctDNA-Guided Adjuvant Bladder Cancer — First Liquid Biopsy-Biomarker-Selected Immunotherapy Approval

On May 15, 2026, the FDA approved atezolizumab (Tecentriq, Genentech/Roche) and its subcutaneous formulation atezolizumab + hyaluronidase-tqjs (Tecentriq Hybreza) for adjuvant treatment of adults with muscle-invasive bladder cancer (MIBC) who are at high risk of recurrence after cystectomy, based on circulating tumor DNA molecular residual disease (ctDNA MRD) positivity. This is the first FDA approval using a ctDNA liquid biopsy companion diagnostic to select patients for immunotherapy in the adjuvant setting — a landmark precision oncology milestone. The approval is supported by data from the Phase 3 IMvigor011 trial (Genentech), which showed: 36% reduction in risk of disease recurrence or death (HR 0.64, p<0.05) and 41% reduction in risk of death (HR 0.59) in the ctDNA-positive population. Median disease-free survival was 9.9 months for atezolizumab vs. 4.8 months for placebo. The FDA simultaneously approved Natera's Signatera ctDNA MRD assay as the companion diagnostic for patient selection. Patients who are ctDNA-positive after cystectomy have significantly higher recurrence risk and derive the greatest benefit from adjuvant checkpoint inhibitor therapy — addressing a precision medicine challenge that standard pathologic staging cannot resolve. Bladder cancer is the 10th most common cancer globally, with approximately 83,000 new diagnoses and 17,000 deaths in the US annually; MIBC carries a 5-year survival rate of approximately 50% with cystectomy alone. This approval validates ctDNA as an actionable biomarker for post-surgical treatment decisions, with implications for future oncology drug development across multiple tumor types.